#USA #Miami #SimBioSys #TumorSight #AI Digital Twin

SimBioSys Showcases Revolutionary AI Technology at Miami Breast Cancer Conference

Introduction

At the 43rd Annual Miami Breast Cancer Conference® held on March 5–8, 2026, in Miami, FL, SimBioSys presented compelling evidence of its innovative AI tool, TumorSight® Viz, designed to enhance surgical planning for early-stage breast cancer. The findings are the result of a multi-institutional clinical study assessing the efficacy of AI in comparison to experienced radiologists.

The Significance of the Study

The abstract titled "An AI Digital Twin Compares Favorably to Radiologists for Landmark Identification and Measurement in Early-Stage Breast Cancer" was proudly showcased as Poster #040. This research highlights the capacity of TumorSight® Viz to create accurate three-dimensional representations from standard breast MRI scans, providing anatomical insights critical for preoperative decision-making.

Stacey Stevens, President and CEO of SimBioSys, emphasized, “This clinical evidence marks a pivotal point in validating how AI-generated digital twins can offer reproducible insights into tumor anatomy similar to those provided by radiologists.”

Key Findings

The retrospective analysis yielded remarkable results, indicating that the performance of TumorSight® Viz stands shoulder to shoulder with expert radiologists:

• - AI Performance: The AI tool’s measurements aligned closely within the variability range of assessments made by U.S.-certified, fellowship-trained breast radiologists.
• - High Spatial Concordance: A surface Dice score of 0.92 showcased an outstanding level of agreement between the AI's tumor delineation and those confirmed by expert professionals.
• - Consistency Across Platforms: The AI’s performance proved stable across various imaging systems, regardless of manufacturer, tumor subtype, or clinical site.
• - Rapid Output: Following the MRI upload, TumorSight® Viz was able to deliver landmark features and measurements in a matter of minutes.

Implications for Breast Cancer Care

The implications of these findings cannot be overstated. Accurate tumor visualization and quantification are crucial for making surgical decisions. The ability of technologies like TumorSight® Viz to replicate radiologists' assessments may significantly enhance collaboration and clarity within multidisciplinary care teams.

Dr. Barry Rosen, Chief Medical Officer of SimBioSys and a breast surgical oncologist, remarked, “Technologies that can reliably mirror radiologist assessments have the potential to improve clarity, reproducibility, and communication across care teams.”

The Road Ahead

This study adds to a growing body of evidence supporting the effectiveness of AI-driven tools in the field of quantitative imaging, underscoring SimBioSys's mission to integrate data-driven decision support within breast cancer treatment. Their FDA-cleared TumorSight® Viz platform is revolutionizing the way healthcare professionals approach cancer care, providing tailored insights that bolster confidence and precision in treatment planning.

Conclusion

As the intersection of AI technology and healthcare continues to evolve, SimBioSys’s activities illuminate a path towards more informed, effective cancer treatment options. With a commitment to advancing cancer care through innovation, the team at SimBioSys is poised to lead the charge towards a more precise and personalized approach to oncology.

For further information on SimBioSys and its groundbreaking solutions, visit www.simbiosys.com.